
Biosynex SA
PAR:ALBIO

Net Margin
Biosynex SA
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | Company | Market Cap |
Net Margin |
||
---|---|---|---|---|---|
FR |
![]() |
Biosynex SA
PAR:ALBIO
|
22.7m EUR |
-43%
|
|
US |
![]() |
Abbott Laboratories
NYSE:ABT
|
230.8B USD |
32%
|
|
US |
![]() |
Intuitive Surgical Inc
NASDAQ:ISRG
|
184.6B USD |
28%
|
|
US |
![]() |
Boston Scientific Corp
NYSE:BSX
|
151.4B USD |
12%
|
|
US |
![]() |
Stryker Corp
NYSE:SYK
|
144.9B USD |
12%
|
|
IE |
![]() |
Medtronic PLC
NYSE:MDT
|
110.2B USD |
14%
|
|
DE |
![]() |
Siemens Healthineers AG
XETRA:SHL
|
52.2B EUR |
9%
|
|
US |
![]() |
Becton Dickinson and Co
NYSE:BDX
|
48.6B USD |
7%
|
|
US |
![]() |
Edwards Lifesciences Corp
NYSE:EW
|
44.3B USD |
75%
|
|
US |
![]() |
IDEXX Laboratories Inc
NASDAQ:IDXX
|
42.4B USD |
23%
|
|
CN |
![]() |
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
273.8B CNY |
31%
|
Biosynex SA
Glance View
Biosynex SA engages in the development, production, and distribution of Rapid Diagnostics Tests (RDTs) for pathologies. The company is headquartered in Illkirch-Graffenstaden, Grand Est. The company went IPO on 2011-03-21. The Company’s products are used by biological and analytical services laboratories, obstetric units and emergency units, as well as in medical resource-limited settings. Biosynex SA specializes in four fields: tropical diseases, emergency markers, infectious diseases and autoimmunity. The Company’s products include Amnioquick (Obstetrics); Immunoquick Malaria Falciparum and Immunoquick Malaria +4 (Parasitology); Immunoquick Elifa HSV IGG, Immunoquick Elifa EBV G and Immunoquick Mono (Virology); Immunoquick Filtration CELIAC IgA and Immunoquick TG (Autoimmunology); and Immunoquick Tetanus (Bacteriology). The company operates through Fumouze Diagnostics and SR2B.

See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Biosynex SA's most recent financial statements, the company has Net Margin of -42.8%.